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Background: Ethiopia is one of the most seriously HIV affected countries in Sub-Saharan Africa. Anemia is a known
predictor of disease progression and death among HIV infected patients. In this study, we investigated the magnitude
and correlates of anemia among HIV infected patients receiving HAART at a referral hospital in Ethiopia.
Methods: A retrospective cohort study was conducted from November 2011 to February 2012 in Zewditu Memorial
Hospital, Addis Ababa, Ethiopia. Records of 1061 patients on HAART were selected using simple random sampling
technique. Socio-demographic and clinical characteristics of the study patients were collected using standardized data
extraction instrument. Data were analyzed using STATA version 11.0. Odds ratios with 95% confidence intervals were
used to quantify the strength of association between anemia and its potential predictors.
Results: The prevalence of anemia at baseline was 42.9%. However, the prevalence significantly decreased to 20.9% at
6 months (p < 0.001) and to 14.3% at 12 months (p = 0.001) after HAART initiation. At baseline, male sex (AOR = 1.55;
95% CI: 1.18-2.03), clinical stage III/IV (AOR = 2.03; 95% CI: 1.45-2.83) and TB co-infection (AOR = 1.52; 95% CI: 1.08-2.13)
were independently associated with the odds of being anemic. After 6 months of HAART, male sex (AOR = 1.59; 95% CI:
1.13-2.23), baseline anemia (AOR = 2.38; 95% CI: 1.71-3.33) and TDF-based HAART (AOR = 2.87; 95% CI: 1.80-4.60) were
independently associated with the odds of being anemic. Besides, anemia was independently associated with older
age at 6 months. After 12 months of HAART, baseline anemia (AOR = 2.01; 95% CI: 1.36-2.97), age group 25–34 years
(AOR = 5.92; 95% CI: 1.39-25.15), age group 45–54 years (AOR = 4.78; 95% CI: 1.07-21.36), CD4 count below 200 cells/mm3
(AOR = 2.15; 95% CI: 1.21-3.82) and 200–350 cells/mm3 (AOR = 1.91; 95% CI: 1.13-3.25) were independently associated
with the odds of being anemic.
Conclusions: Although a remarkable reduction in the prevalence of anemia was observed following initiation of HAART,
a significant proportion of HIV patients remained anemic after 12 months of HAART suggesting the need for routine
screening and proper treatment of anemia to mitigate its adverse effects.
Keywords: HIV, HAART, Anemia, EthiopiaBackground
Complications of human immunodeficiency virus (HIV)
infection include hematological abnormalities manifested
by pancytopenia, anemia being the leading abnormality
[1-3]. However, the prevalence of anemia in HIV patients
varies considerably, ranging from 1.3% to 95% [4]. Several
factors including stage of HIV, age and sex are said to ac-
count for the variations in HIV prevalence [4]. The causes* Correspondence: mulg2002@yahoo.com
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unless otherwise stated.of anemia have been reported to be multifactorial. Direct
effects of HIV and its viral proteins as well as immune
dysregulations during HIV infection were found to be
responsible for bone marrow suppression [5,6]. More-
over, opportunistic infections of the bone marrow with
pathogens such as Mycobacterium avium complex, Parvo-
virus B-19, Cytomegaloviruses, Cryptococcus neoformans
and Histoplasma capsulatum were reported to cause ab-
normalities in blood cell counts [6,7]. Drugs used to treat
HIV infection and its complications are also known to
cause bone marrow suppression [7,8]. It is widely knownThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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treatment (HAART) regimen is associated with significant
reduction of hemoglobin (Hgb) level [7,9,10].
Anemia is associated with impaired physical function-
ing, psychological distress and poor quality of life [7].
Besides, independent of CD4 and viral load counts,
anemia has been reported to predict HIV progression to
acquired immune deficiency syndrome (AIDS) with poor
survival [4,7,11,12]; on the other hand, treatment of
anemia was observed to be associated with reversal of
increased risk of death [13]. In addition, anemia was re-
ported to be strongly and consistently associated with
HIV disease progression and death despite HAART initi-
ation [8], suggesting the need for routine screening and
treatment of anemia in HIV patients on HAART. Preva-
lence of anemia among Ethiopian men and women aged
15–49 years was documented to be 11% and 17%, re-
spectively [14]. Regional differences were remarkable
and the prevalence of anemia in men and women aged
15–49 years in Addis Ababa were 3% and 9%, respect-
ively [14]. In addition, recent study reported a considerably
higher prevalence of anemia among HIV-infected
antiretroviral-naïve adult Ethiopians (38% for men and
62% for women) [15]. Ethiopians’ normal immunohemato-
logical profile is known to be lower than the corresponding
values in Caucasians [16]. Besides, AZT-based HAART is
one of the first line regimens recommended for treating
HIV infected adults [17]. However, the magnitude of
anemia and its risk factors among HIV patients on
HAART are not well document in Ethiopia. Thus, this
study investigated the prevalence of anemia and its associ-
ated factors among HIV infected patients receiving
HAART in a referral hospital in Ethiopia.
Methods
Study setting and study population
A retrospective cohort study was conducted by review-
ing hospital data of patients who were receiving HAART
at the HIV clinic of Zewditu Memorial Hospital, Addis
Ababa, Ethiopia from November 2011 to February 2012.
The Hospital launched Antiretroviral Therapy (ART) in
July 2003 as the first pilot site in the country. Among
15,000 HIV infected adults on care at the Hospital,
9,287 were on ART during data collection. Among those
on ART, a total of 1061 HIV infected adults were ran-
domly selected and included in this study. Sample size
was estimated using a single population proportion for-
mula, taking p=46% (expected prevalence of anemia at
baseline) [1], 3% level of precision (d) with 95% confi-
dence interval. Patients transferred in from other health
institutions, patients who started ART in the hospital be-
fore March 1, 2005 or after November 30, 2010 and pa-
tients who were pregnant at baseline or during the
follow up visits were excluded from the study.Data collection
The data was extracted using a standardized instrument
by three ART nurses. The collected information includes
socio-demographics, clinical characteristics, medication
use and immunohematological profile of patients at base-
line, 6 and 12 months after initiation of HAART.
Hemoglobin (Hgb) values, red blood cell count, white
blood cell counts with absolute CD4 cells and CD8 cells,
and platelets were determined using the hematology
analyzer Cell-Dyn 1800 (Abbott Laboratories Diagnostics
Division, USA) whereas CD4+ T cells were assayed using
the BD FACSCOUNT system (Becton Dickenson and
Company, California, USA). To ensure good quality data,
training of data collectors, pre- testing of data extraction
instrument and continuous supervision of the data collec-
tion process was carried out. Data were checked for
missed values and outliers during data management.Definition of outcome variable and statistical analysis
Data were computerized using Epidata version 3.1 and
STATA version 11 (StataCorp LP, college station, TX)
was used for data analysis. Anemia was defined based on
hematological reference values for adult Ethiopian popu-
lation [16]. Accordingly, anemia was defined as Hgb
concentration less than or equal to 13.9 g/dl for adult
males and less than or equal to 12.2 g/dl for adult fe-
males. It was further classified into mild (10–12.2 g/dl for
females and 10–13.9 g/dl for males), moderate (8–10 g/dl)
and severe (<8 g/dl) for both sexes.
The effect of different risk factors on the odds of being
anemic were investigated at baseline, at 6 months and at
12 months following initiation of HAART. Odds ratio
with 95% confidence interval was used to quantify the
strength of association between anemia and its potential
predictors. Variables that were found significantly associ-
ated with the outcome variable (p < 0.05) in the bivariate
analysis as well as variables that were reported to be asso-
ciated with anemia in previous studies and that were clin-
ically relevant for the occurrence of anemia were included
in the multivariable logistic regression model to obtain ad-
justed effects. Since height was not recorded for the ma-
jority of the study participants, missing values for body
mass index (BMI) were coded as a separate category be-
fore including BMI in multivariable logistic regression so
that data from all study participants can be used.Ethical consideration
Study protocol was approved by the Institutional Review
Board of Aklilu Lemma Institute of Pathobiology, Addis
Ababa University and Addis Ababa City Administration
Health Bureau. Identifiers of the study participants were
not collected to maintain confidentiality.
Table 2 Baseline clinical characteristics of HIV infected
patients on HAART at Zewditu Memorial Hospital, Addis
Ababa, Ethiopia, 2012
Variable Frequency Percent
WHO clinical stage (n = 1059)
Stage I /II 396 37.4
Stage III /IV 663 62.6




*BMI (Kg/m2) (n = 243)
<18.5 54 22.2
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Baseline characteristics of patients
Demographic and clinical characteristics of the study pa-
tients at treatment initiation are presented in Table 1
and Table 2, respectively. Of the total 1061 study patients,
60% were females, 76.0% were in the age range of 25–49
years and the overall age range was 17–88 years. Majority
(62.6%) of the patients were classified as WHO clinical
stage III/IV and 79.4% had a CD4 cell count of less than
200 cells/mm3. The mean Hgb value was 12.9 (sd = 2.4 g/
dl) while the mean CD4 cell count was 139.8 (sd = 78.8)
cells/mm3. Five hundred and forty-four (52.0%) of the
study patients were co-infected with different types of op-
portunistic infections.Table 1 Baseline socio-demographic characteristics of HIV
infected patients on HAART at Zewditu Memorial
Hospital, Addis Ababa, Ethiopia, 2012
Variable Frequency Percent
Gender (n = 1061)
Female 632 59.6
Male 429 40.4












Educational status (n = 1008)




Marital status (n = 1031)










Opportunistic infections (n = 1060)
No OI 508 47.9
Candidiasis 251 23.7




Bacterial pneumonia 33 3.1
Other OIs 30 2.8
OI: Opportunistic Infection; *BMI: Body mass index.Anemia before HAART initiation
A total of 455 (42.9%) patients were anemic at baseline
of which 360 (34.0%) had mild, 71 (6.7%) had moderate
and 24 (2.3%) had severe anemia. The overall prevalence
of anemia was higher in males (50.4%) than in females
(37.8%) (p < 0.001). Significantly higher proportion of fe-
males had moderate and severe forms of anemia compared
to males: moderate anemia was 7.9% among females and
4.9% among males (p < 0.001) and severe anemia (2.9%
among females and 1.4% among males (p < 0.001).
Different factors were observed to be associated with
being anemic before HAART initiation (Table 3). In uni-
variable analysis, increased risk of anemia at baseline
was associated with male sex (OR = 1.67; 95% CI: 1.30-
2.14), age greater than 55 years (OR = 2.40; 95% CI:
1.06-5.41), clinical stage III/IV (OR = 2.35; 95% CI: 1.81-
3.06), BMI <18.5 (OR = 2.32; 95% CI: 1.24-4.36) and the
presence of opportunistic infections such as TB (OR =2.07;
95% CI: 1.54-2.80) and candidiasis (OR = 1.44; 95% CI:
1.08-1.91). CD4 count <200 cells/mm3 and 200-350 cells/
mm3 are associated with decreased odds of being anemic.
In multivariable logistic regression analysis, male sex, clin-
ical stage III/IV and TB co-infection were independently as-
sociated with increased odds of being anemic whereas CD4
Table 3 Predictors of anemia in HIV Infected patients at
before HAART initiation at Zewditu Memorial, Addis
Ababa, Ethiopia 2012
Variable Crude OR (95% CI) AOR (95% CI)
Gender
Female 1.00 1.00
Male 1.67 (1.30-2.14) 1.55 (1.18-2.03)
Age (in years)
15-24 1.00 1.00
25-34 0.99 (0.58-1.71) 0.99 (0.56-1.77)
35-44 1.46 (0.85-2.52) 1.46 (0.82-2.60)
45-54 1.40 (0.77-2.55) 1.21 (0.64-2.29)
55+ 2.40 (1.06-5.41) 2.06 (0.88-4.82)
WHO clinical stage
Stage I/II 1.00 1.00
Stage III/IV 2.35 (1.81-3.06) 2.03 (1.45-2.83)
CD4 cell count (cells/mm3)
≥350 1.00 1.00
200-350 0.13 (0.03-0.47) 0.16 (0.04-0.61)
0-199 0.22 (0.06-0.81) 0.25 (0.07-0.93)
BMI
Normal 1.00 1.00
Underweight 2.32 (1.24-4.36) 1.83 (0.92-3.65)
Overweight 0.95 (0.42-2.12) 1.14 (0.49-2.65)
OI
Candidiasis 1.44 (1.08-1.91) 1.09 (0.78-1.52)
Herpes zoster 0.86 (0.65-1.14) 0.86 (0.64-1.17)
TB 2.07 (1.54-2.80) 1.52 (1.08-2.13)
Diarrhea 0.87 (0.52-1.46) 0.72 (0.40-1.32)
Fever 1.19 (0.67-2.11) 1.00 (0.52-1.96)
Pneumonia 1.84 (0.91-3.71) 1.94 (0.90-4.18)
Toxoplasmosis 1.34 (0.50-3.59) 1.03 (0.36-2.93)
OR: Odds ratio; AOR: Adjusted odds ratio; BMI: Body mass index;
OI: opportunistic infections.
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pendently associated with reduced odds of being anemic in
the multivariable analysis.
Anemia after HAART initiation
A total of 980 (92.4%) of the study participants had Hgb
measurements at 6 months of HAART initiation. Of
these, 970 (99%) had Hgb measurements at baseline.
And of the 896 (84.4%) patients who had Hgb measure-
ments at 12 month, 888 (99.1%) had Hgb measurements
both at baseline and at 6 months of HAART treatment.
Patients with missing Hgb measurements at 6 month (81
patients) were more likely to be those in the age group of25-34 years, those having a CD4 cell counts of ≥350 cells/
mm3, those who were not on co-trimoxazole prophylactic
treatment and those who were receiving d4T based
HAART regimen. However, there was no statistically sig-
nificant difference in the sex, BMI values, fluconazole
treatment status, TB treatment status and anti-microbial
treatment status between patients included and excluded
from the study of anemia at the 6 month. During the study
period, changes were made to the regimen of 85 patients.
Of the 60 patients for whom drug regimen was changed in
the first 6 months, 25(41.7%) were those who were anemic
at baseline. Treatment regimen was changed for 40 of the
patients who were on AZT based regimen (15 (37.5%)
were anemic at baseline), for 16 of those on d4T- based
regimen (9(56.3%) were anemic at baseline) and for 4 of
those on TDF- based regimen (1(25.0%) were anemic at
the baseline). After 6 months, 25 patients have changed
their treatment regimens of whom 18 (72%) were pa-
tients on d4T- based regimen and 7 (28%) were those on
AZT- based regimen. The mean (sd) Hgb values of the
study patients at 6 and 12 months were 14.0 (2.3) g/dl and
14.4 (1.9) g/dl, respectively.
The overall prevalence of anemia significantly de-
creased after HAART initiation. The prevalence declined
from 42.9% at baseline to 20.9% at 6 months (p < 0.001)
and to 14.3% at 12 months (p = 0.001). There was also a
consistent decrease in the prevalence of mild, moderate
and severe anemia after treatment with HAART (Figure 1).
Similar to the baseline level, anemia remained to be more
prevalent among males compared to females after
6 months of treatment with HAART. At 6 months fol-
lowing initiation of HAART, 25.4% of males and 17.9%
of females were anemic. At the same time, more males
than females had mild anemia (24.2% versus 15.4%),
moderate anemia (2.4% versus 1.2%) and severe anemia
(0.2% versus 0.0%) (p = 0.002). However, there was no
statistically significant difference in the prevalence of
anemia between males and females at 12 months of
HAART.
Risk factors for anemia after initiation of HAART are
shown in Table 4. At 6 months of HAART, male sex
(AOR = 1.59; 95% CI: 1.13-2.23), anemia at baseline
(AOR = 2.38; 95% CI: 1.71-3.33), and TDF- based
HAART regimen (AOR = 2.87; 95% CI: 1.80-4.60) were
independent predictors of anemia. Besides, at 6 months,
older age was independently associated with increased
odds of being anemic. At 12 months, anemia at baseline
(AOR= 2.01; 95% CI: 1.36-2.97), being in the age range of
25–34 years (AOR = 5.92; 95% CI: 1.39-25.15), being in
the age range of 45–54 years (AOR = 4.78; 95% CI: 1.07-
21.36), CD4 count below 200 cells/mm3 (AOR = 1.91; 95%
CI: 1.13-3.25) and 200–350 cells/mm3 (AOR = 2.15; 95%
CI: 1.21-3.82) were independently associated with in-
creased odds of being anemic.
Figure 1 Changes in the prevalence of anemia according to severity grades after HIV infected patients started HAART in Zewditu Memorial
Hospital, Addis Ababa, Ethiopia, 2012.
Table 4 Predictors of anemia in HIV Infected patients at 6 and 12 months of HAART initiation at Zewditu Memorial
Hospital, Addis Ababa, Ethiopia, 2012
Variable 6 months 12 months
Crude OR (95% CI) AOR (95% CI Crude OR (95% CI) AOR (95% CI
Gender
Female 1.00 1.00 1.00 1.00
Male 1.56 (1.16-2.11) 1.59 (1.13-2.23) 1.19 (0.84-1.68) 1.01 (0.68-1.50)
Age (in years)
15-24 1.00 1.00 1.00 1.00
25-34 2.99 (1.17-7.69) 3.50 (1.31-9.33) 4.14 (1.26-13.55) 5.92 (1.39-25.15)
35-44 3.14 (1.22-8.09) 3.09 (1.16-8.22) 2.76 (0.83-9.15) 3.27 (0.76-14.11)
45-54 4.40 (1.65-11.73) 4.32 (1.56-11.99) 4.23 (1.23-14.52) 4.78 (1.07-21.36)
55+ 4.07 (1.27-13.00) 3.32 (0.99-11.16) 2.99 (0.67-13.29) 2.90 (0.48-17.54)
CD4 count (cells/mm3)
≥350 1.00 1.00 1.00 1.00
200-350 1.11 (0.72-1.75) 1.10 (0.69-1.75) 2.07 (1.24-3.46) 1.91 (1.13-3.25)
0-199 1.29 (0.82-2.02) 1.23 (0.76-1.99) 2.31 (1.34-3.99) 2.15 (1.21-3.82)
Baseline anemia
Not anemic 1.00 1.00 1.00 1.00
Anemic 2.64 (1.95-3.58) 2.38 (1.71-3.33) 1.74 (1.23-2.45) 2.01(1.36-2.97)
Medication history
Prophylactic
Co-trimoxazole 0.81 (0.53-1.25) 0.48 (0.17-1.32) 0.68 (0.40-1.14) 0.81 (0.32-2.11)
Others 0.83 (0.34-2.04) 0.69 (0.27-1.76) 0.28 (0.04-2.14) 0.36 (0.05-2.78)
Non-prophylactic
Anti- TB drug 1.69 (1.08-2.63) 1.11 (0.68-1.82) 2.08 (0.96-4.53) 2.09 (0.90-4.83)
HAART regimen
d4T- based 1.00 1.00 1.00 1.00
AZT- based 0.88 (0.62-1.25) 1.19 (0.81-1.76) 1.15 (0.78-1.69) 1.47 (0.96-2.26)
TDF- based 1.98 (1.30-3.03) 2.87 (1.80-4.60) 0.49 (0.26-0.94) 0.80 (0.40-1.59)
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In this study, we investigated the prevalence of anemia
and its associated factors in a large cohort of HIV in-
fected patients taking HAART over 12 months. A large
proportion of our study patients had anemia at baseline
and subsequent follow-up time points. The prevalence
of anemia before initiation of HAART in this study was
comparable with the prevalence reported in other stud-
ies [1,18,19]. However, it was much higher compared to
the prevalence reported by Gedefaw et al. from Ethiopia
[20], Firnhaber et al. [21] and Mata-Marín et al. [22]
elsewhere, who reported a prevalence of 29.9%, 12.0%
and 20.0%, respectively. The reasons for the observed
difference might be due to the heterogeneity of study
population and differences in the study settings in terms
of nutritional status, stages of HIV infection and health in-
terventions including treatment of hematological abnor-
malities. For example, both Firnhaber et al. [21] and Mata-
Marin et al. [22] excluded patients with illnesses including
opportunistic infections who could have contributed to
higher anemia prevalence. Furthermore, the patients in
Firnhaber et al. study were from nine countries with di-
verse geographic settings. A direct comparison of preva-
lence of anemia in different studies is difficult because of
differences in the study population, presentation of data
and definition used for anemia. This study used the defin-
ition that was proposed specifically for Ethiopian popula-
tion to define anemia [16].
Results from this study show a remarkable reduction
in the prevalence of anemia after initiation of HAART.
In agreement with our observation, in other studies, the
prevalence of anemia in HAART naïve was significantly
higher compared to HAART experienced patients [1,23].
The reduction in opportunistic infections including TB,
candidiasis and others, as well as the reduction of in-
flammatory cytokines such as tumor necrosis factor
(TNF) that are implicated in the suppression of erythro-
poiesis could be mechanisms that may account for the im-
provement of anemia after initiation of HAART [24,25].
Despite a significant reduction in the prevalence of anemia
at 12 months, close to 15% of the patients had anemia im-
plying the need for routine screening of anemia and subse-
quent investigation of its causes. In this study, based on
the data we have, we were not able to determine the spe-
cific reasons why these patients had anemia despite treat-
ment with HAART. After 12 months of HAART, low CD4
count was a predictor of anemia suggesting poor recovery
and probably high viral load in those patient with anemia
after 12 months of HAART. Data on viral load would have
been useful but this test is not routinely done at the study
site and we were not able to include in the analysis.
Similar to this study, some studies reported a high
prevalence of anemia in males compared to females and
attributed it to the fact that lower Hgb level is used todefine anemia in women than men [26,27]. However,
many previous studies reported a high prevalence of
anemia in females compared to male HIV infected pa-
tients [8,28]. The proposed reason was the presence of
menstrual blood loss and to the drains on iron stores
that occur with pregnancy and delivery in women. How-
ever, none of the above studies described the prevalence
of anemia according to severity grades. In our study,
moderate and severe forms of anemia were higher in fe-
males compared to males both before and after 6 months
on HAART. The absence of significant difference in the
risk of anemia at 12 months on HAART between male
and female patients seen in this study may suggest the
role of HAART to improve anemia after 12 months.
We observed an increase in the risk of anemia with age.
The hematopoietic stem cell displays increasing erythro-
poietin (EPO) resistance with increasing age and further
aging is associated with increased pro-inflammatory cyto-
kine expression many of which contributing to EPO resist-
ance [29], thereby resulting in anemia.
Different studies reported association between in-
creased incidence of low blood cell counts with progres-
sive immunologic deterioration and advanced disease
due to HIV [2,8,20]. It was suggested that increasing
viral burden as HIV disease progresses could cause
hematological abnormality by increasing cytokine medi-
ated myelosuppression [25]. In this study, low CD4 cell
count was associated with anemia at baseline although
the reasons for such association are not clear. At base-
line, the presence of opportunistic infections such as TB
and fungal infections like candidiasis might play a major
role in the pathogenesis of anemia than the deterioration
in immunity as proposed by Scadden and his group [30].
However, an increasing risk in anemia with decreasing
values of CD4 cell count was seen at 12 months; and the
observed association between anemia and lower CD4
cell count at 12 month might be related to poor im-
munological recovery and high viral load rather than to
opportunistic infections. Increased risk of anemia in pa-
tients who were on anti-TB drugs has been observed in
this study and it may be related to the anti-TB drugs.
More importantly, TB is a chronic infection known to
cause moderate degree of anemia [31] which is reversible
on treatment.
The absence of significant association between treat-
ment with AZT and anemia in the current study despite
its frequent association with bone marrow suppression
has also been previously described [32,33]. The effect of
AZT may be modest when taken as HAART than ad-
ministered as a single dose. However, the association of
anemia with TDF-based regimen in this study, despite
its low cytotoxicity towards erythroid progenitor cells
and its effectiveness in terms of viral suppression, CD4
response and reduced adverse events compared to AZT
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study.
This study is based on a large cohort of HIV patients
on HAART. However, data were collected for routine
clinical care, and hence, other important variables, not-
ably viral load are lacking. Moreover, the majority of pa-
tients had no data on BMI. Nevertheless, this study
highlights the burden of anemia among HIV patients be-
fore and after HAART.
Conclusions
In conclusion, anemia is a common manifestation of HIV
infection both before and after initiation of HAART in the
study setting. The treatment of HIV infected patients with
HAART has resulted in a remarkable reduction in the
prevalence of anemia after 12 months. However, a sub-
stantial proportion of patients had anemia after 12 months
of HAART, suggesting the need for routine screening of
anemia, investigating its causes and instituting appropriate
treatment to mitigate the adverse effects of anemia. Con-
sidering the high burden even after a prolonged HAART,
there is a need for developing a comprehensive screening,
treatment and monitoring protocol for anemia.
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